Compare Stocks → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ADDXFOTCMKTS:ASPCFNASDAQ:CLRBNASDAQ:ENVBNASDAQ:XCUR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADDXFAddex Therapeutics$0.99$0.99$0.99▼$0.99N/A0.25N/AN/AASPCFAcerus Pharmaceuticals$0.22$0.22$0.22▼$8.16$1.70M0.691,500 shsN/ACLRBCellectar Biosciences$3.08-1.0%$3.65$1.33▼$4.45$99.36M0.921.66 million shs627,196 shsENVBEnveric Biosciences$0.88-1.8%$1.05$0.65▼$6.98$6.42M0.853.50 million shs39,579 shsXCURExicure$0.54-0.9%$0.62$0.36▼$1.50$4.63M1.31387,149 shs17,345 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADDXFAddex Therapeutics0.00%0.00%0.00%0.00%0.00%ASPCFAcerus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CLRBCellectar Biosciences-2.51%-6.04%-23.21%-7.44%+115.97%ENVBEnveric Biosciences+4.23%-1.49%-20.58%+1.98%-45.61%XCURExicure+0.11%-13.01%-14.05%-4.54%-42.81%The system that called 2023’s top 7 stocks is at it again… (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACLRBCellectar Biosciences0.8787 of 5 stars3.52.00.00.00.60.00.6ENVBEnveric Biosciences1.6777 of 5 stars3.53.00.00.02.20.00.6XCURExicure2.759 of 5 stars0.04.00.04.71.91.71.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADDXFAddex TherapeuticsN/AN/AN/AN/AASPCFAcerus PharmaceuticalsN/AN/AN/AN/ACLRBCellectar Biosciences3.00Buy$20.00549.35% UpsideENVBEnveric Biosciences3.00Buy$10.001,035.07% UpsideXCURExicureN/AN/AN/AN/ACurrent Analyst RatingsLatest XCUR, ENVB, CLRB, ADDXF, and ASPCF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $28.003/28/2024CLRBCellectar BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $12.003/4/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.001/30/2024ENVBEnveric BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AASPCFAcerus Pharmaceuticals$2.12M0.80N/AN/A($3.38) per share-0.07CLRBCellectar BiosciencesN/AN/AN/AN/A($0.36) per shareN/AENVBEnveric BiosciencesN/AN/AN/AN/A$0.71 per shareN/AXCURExicure$28.83M0.16N/AN/A$3.00 per share0.18Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADDXFAddex TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AASPCFAcerus Pharmaceuticals-$33.82M-$3.57N/A∞N/A-924.33%N/A-74.62%N/ACLRBCellectar Biosciences-$37.98M-$3.10N/AN/AN/AN/A-3,821.29%-280.23%5/2/2024 (Estimated)ENVBEnveric Biosciences-$17.29M-$8.11N/AN/AN/AN/A-349.01%-187.74%5/20/2024 (Estimated)XCURExicure-$2.58M$1.680.32∞N/AN/AN/AN/A7/12/2024 (Estimated)Latest XCUR, ENVB, CLRB, ADDXF, and ASPCF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023CLRBCellectar Biosciences-$0.59-$0.66-$0.07-$0.92N/AN/A3/25/2024Q4 2023ENVBEnveric Biosciences-$1.55-$1.46+$0.09-$1.46N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADDXFAddex TherapeuticsN/AN/AN/AN/AN/AASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADDXFAddex TherapeuticsN/AN/AN/AASPCFAcerus PharmaceuticalsN/A0.670.34CLRBCellectar BiosciencesN/A0.810.81ENVBEnveric BiosciencesN/A1.531.53XCURExicureN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipADDXFAddex TherapeuticsN/AASPCFAcerus PharmaceuticalsN/ACLRBCellectar Biosciences16.41%ENVBEnveric Biosciences13.82%XCURExicure42.82%Insider OwnershipCompanyInsider OwnershipADDXFAddex TherapeuticsN/AASPCFAcerus PharmaceuticalsN/ACLRBCellectar Biosciences4.60%ENVBEnveric Biosciences1.20%XCURExicure8.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADDXFAddex Therapeutics26N/AN/ANot OptionableASPCFAcerus Pharmaceuticals147.71 millionN/ANot OptionableCLRBCellectar Biosciences2032.26 million30.78 millionOptionableENVBEnveric Biosciences77.29 million7.21 millionNot OptionableXCURExicure78.65 million7.92 millionNot OptionableXCUR, ENVB, CLRB, ADDXF, and ASPCF HeadlinesSourceHeadlineExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Kbusinesswire.com - April 22 at 4:01 PMExicure gets grant for liposomal particles for gene regulation with spherical geometrypharmaceutical-technology.com - April 18 at 9:05 AMExicure (NASDAQ:XCUR) Shares Down 8.7% americanbankingnews.com - April 18 at 1:34 AMExicure Stock (NASDAQ:XCUR), Short Interest Reportbenzinga.com - February 22 at 7:55 AMExicure inks licensing deal for one of its remaining therapieschicagobusiness.com - February 12 at 7:43 AMWhy FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com - February 6 at 2:15 PMWhy Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarketmsn.com - February 6 at 9:44 AMExicure Inc Announces Licensing Patents for Therapeutic Advancementmsn.com - February 6 at 9:15 AMExicure, Inc. and Bluejay Therapeutics Inc. Enter…pharmiweb.com - February 5 at 10:23 PMExicure, Bluejay Therapeutics Enter Patent License Agreement to Develop Hepatitis Treatmentmarketwatch.com - February 5 at 5:22 PMExicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitisfinance.yahoo.com - February 5 at 5:22 PMBest Undervalued Stocks for February 2024msn.com - February 1 at 1:04 PMExicure, Inc. (XCUR) Stock Price, News, Quote & History - Yahoo Financeca.finance.yahoo.com - December 16 at 8:49 AMWhy Is Exicure (XCUR) Stock Up 57% Today?investorplace.com - December 8 at 10:01 AMExicure: Nonreliance On Previously Issued Financial Statements Or A Related Audit Report Or Completed Interim Reviewcbonds.com - December 3 at 8:28 AMExicure receives Nasdaq delinquency notice on late filing of its form 10-Qmsn.com - November 28 at 5:18 PMExicure Inc XCURmorningstar.com - November 9 at 1:25 PMLacklustre Performance Is Driving Exicure, Inc.'s (NASDAQ:XCUR) 25% Price Dropfinance.yahoo.com - August 29 at 7:04 AMExicure names new CEO, CFO, directors in wake of resignationsmsn.com - August 23 at 4:05 PMExicure First Half 2023 Earnings: US$1.38 loss per share (vs US$3.71 loss in 1H 2022)finance.yahoo.com - August 15 at 7:28 AMExicure: Substantial Financing Needed to Continue Operationsmarketwatch.com - August 11 at 5:38 PMExicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updatebusinesswire.com - August 11 at 5:38 PMExicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - July 14 at 6:09 PMExicure board backs CEO Kim's strategic alternative view for companymsn.com - May 26 at 5:52 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAddex TherapeuticsOTCMKTS:ADDXFAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Acerus PharmaceuticalsOTCMKTS:ASPCFAcerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.Cellectar BiosciencesNASDAQ:CLRBCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Enveric BiosciencesNASDAQ:ENVBEnveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.ExicureNASDAQ:XCURExicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.